All In Biotech

Drug Trial Radar · NCT07283770

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Jul 12, 2027

Study completion Jul 12, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Conditions

  • Cystic Fibrosis

Interventions

  • VX-581Drug

    Suspension for Oral Administration.

  • PlaceboDrug

    Suspension for Oral Administration.

  • D-IVADrug

    Tablet for Oral Administration.

  • TEZDrug

    Tablet for Oral Administration.

  • ELX/TEZ/IVADrug

    Fixed dose combination (FDC) Tablets for Oral Administration.

  • VX-581Drug

    Tablets for Oral Administration.

  • IVADrug

    Tablet for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 8
  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 17
  3. Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day -1 up to Day 17
  4. Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent up to Day 105

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences - Kansas City

    Overland Park, Kansas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.